Skip to main content
Top
Published in: Ophthalmology and Therapy 4/2023

Open Access 09-06-2023 | Edema | ORIGINAL RESEARCH

Foveal Eversion is Associated with High Persistence of Macular Edema and Visual Acuity Deterioration in Retinal Vein Occlusion

Authors: Alessandro Arrigo, Emanuela Aragona, Alessio Antropoli, Lorenzo Bianco, Andrea Rosolia, Andrea Saladino, Francesco Bandello, Maurizio Battaglia Parodi

Published in: Ophthalmology and Therapy | Issue 4/2023

Login to get access

Abstract

Introduction

Foveal eversion (FE) is a recently described optical coherence tomography (OCT) finding associated with negative outcome in diabetic macular edema. The main goal of the present study was to investigate the role of the FE metric in the diagnostic workup of retinal vein occlusion (RVO).

Methods

This study was a retrospective, observational case series. We included 168 eyes (168 patients) affected by central RVO (CRVO) and 116 eyes (116 patients) affected by branch (RVO). We collected clinical and imaging data from CRVO and BRVO eyes affected by macular edema with a minimum follow-up of 12 months. On structural OCT, we classified FE as pattern 1a, characterized by thick vertical intraretinal columns, pattern 1b, presenting thin vertical intraretinal lines, and pattern 2, showing no signs of vertical lines in the context of the cystoid macular edema. For statistical purposes, we considered data collected at baseline, after 1 year and at the last follow-up.

Results

The mean follow-up was 40 ± 25 months for CRVO eyes and 36 ± 24 months for BRVO eyes. We found FE in 64 of 168 CRVO eyes (38%) and in 25 of 116 BRVO eyes (22%). Most of the eyes developed FE during the follow-up. For CRVO eyes, we found 6 eyes (9%) with pattern 1a, 17 eyes (26%) with pattern 1b and 41 eyes (65%) with pattern 2. Of those BRVO eyes with FE, we found 8 eyes (32%) with pattern 1a + 1b and 17 eyes (68%) with pattern 2. In both CRVO and BRVO the presence of FE was significantly associated with higher persistence of macular edema and worse outcome, with FE pattern 2 representing the most severe condition. Remarkably, FE patterns 1a and 1b were characterized by BCVA stability over the follow-up, whereas FE pattern 2 showed significant bestcorrected visual acuity (BCVA) worsening at the end of the follow-up.

Conclusions

FE can be considered a negative prognostic biomarker in RVO, associated with higher persistence of macular edema and worse visual outcome. Müller cell impairment might represent the pathogenic mechanism leading to the loss of macular structural support and impairment of fluid homeostasis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hayreh SS, Zimmerman MB, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol. 1994;117(4):429–41.CrossRefPubMed Hayreh SS, Zimmerman MB, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol. 1994;117(4):429–41.CrossRefPubMed
2.
go back to reference Rogers S, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117(2):313-9.e1.CrossRefPubMed Rogers S, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117(2):313-9.e1.CrossRefPubMed
3.
go back to reference Hayreh SS. Ocular vascular occlusive disorders: natural history of visual outcome. Prog Retin Eye Res. 2014;41:1–25.CrossRefPubMed Hayreh SS. Ocular vascular occlusive disorders: natural history of visual outcome. Prog Retin Eye Res. 2014;41:1–25.CrossRefPubMed
4.
go back to reference Campochiaro PA, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology. 2011;118(10):2041–9.CrossRefPubMed Campochiaro PA, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology. 2011;118(10):2041–9.CrossRefPubMed
5.
go back to reference Haller JA, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117(6):1134-1146.e3.CrossRefPubMed Haller JA, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117(6):1134-1146.e3.CrossRefPubMed
6.
go back to reference Haller JA, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011;118(12):2453–60.CrossRefPubMed Haller JA, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011;118(12):2453–60.CrossRefPubMed
7.
go back to reference Heier JS, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology. 2012;119(4):802–9.CrossRefPubMed Heier JS, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology. 2012;119(4):802–9.CrossRefPubMed
8.
go back to reference Campochiaro PA, et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology. 2014;121(1):209–19.CrossRefPubMed Campochiaro PA, et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology. 2014;121(1):209–19.CrossRefPubMed
9.
go back to reference Boyer D, et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology. 2012;119(5):1024–32.CrossRefPubMed Boyer D, et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology. 2012;119(5):1024–32.CrossRefPubMed
10.
go back to reference Heier JS, et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology. 2014;121(7):1414-1420.e1.CrossRefPubMed Heier JS, et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology. 2014;121(7):1414-1420.e1.CrossRefPubMed
11.
go back to reference Clark WL, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology. 2016;123(2):330–6.CrossRefPubMed Clark WL, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: 52-week results of the VIBRANT study. Ophthalmology. 2016;123(2):330–6.CrossRefPubMed
12.
go back to reference Schmidt-Erfurth U, et al. Guidelines for the management of retinal vein occlusion by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2019;242(3):123–62.CrossRefPubMed Schmidt-Erfurth U, et al. Guidelines for the management of retinal vein occlusion by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2019;242(3):123–62.CrossRefPubMed
13.
go back to reference Arrigo A, Bandello F. Retinal vein occlusion: drug targets and therapeutic implications. Expert Opin Ther Targets. 2021;25(10):847–64.CrossRefPubMed Arrigo A, Bandello F. Retinal vein occlusion: drug targets and therapeutic implications. Expert Opin Ther Targets. 2021;25(10):847–64.CrossRefPubMed
14.
go back to reference Tadayoni R, et al. Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER study. Ophthalmology. 2017;124(12):1778–87.CrossRefPubMed Tadayoni R, et al. Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER study. Ophthalmology. 2017;124(12):1778–87.CrossRefPubMed
15.
go back to reference Chatziralli I, Theodossiadis G, Parikakis E, Mitropoulos PG, Theodossiadis P. Long-term anatomical and functional outcomes in patients with ischemic central retinal vein occlusion treated with anti-vascular endothelial growth factor agents. Ophthalmic Res. 2017;58(4):203–8.CrossRefPubMed Chatziralli I, Theodossiadis G, Parikakis E, Mitropoulos PG, Theodossiadis P. Long-term anatomical and functional outcomes in patients with ischemic central retinal vein occlusion treated with anti-vascular endothelial growth factor agents. Ophthalmic Res. 2017;58(4):203–8.CrossRefPubMed
16.
go back to reference Khayat M, Williams M, Lois N. Ischemic retinal vein occlusion: characterizing the more severe spectrum of retinal vein occlusion. Surv Ophthalmol. 2018;63(6):816–50.CrossRefPubMed Khayat M, Williams M, Lois N. Ischemic retinal vein occlusion: characterizing the more severe spectrum of retinal vein occlusion. Surv Ophthalmol. 2018;63(6):816–50.CrossRefPubMed
17.
18.
go back to reference Rezar S, et al. Anti-VEGF treatment in branch retinal vein occlusion: a real-world experience over 4 years. Acta Ophthalmol. 2015;93(8):719–25.CrossRefPubMed Rezar S, et al. Anti-VEGF treatment in branch retinal vein occlusion: a real-world experience over 4 years. Acta Ophthalmol. 2015;93(8):719–25.CrossRefPubMed
19.
go back to reference Arrigo A, et al. Real-life management of central and branch retinal vein occlusion: a seven-year follow-up study. Thromb Haemost. 2021;121(10):1361–6.CrossRefPubMed Arrigo A, et al. Real-life management of central and branch retinal vein occlusion: a seven-year follow-up study. Thromb Haemost. 2021;121(10):1361–6.CrossRefPubMed
22.
go back to reference Distler C, Dreher Z. Glia cells of the monkey retina—II. Müller cells. Vis Res. 1996;36(16):2381–94.CrossRefPubMed Distler C, Dreher Z. Glia cells of the monkey retina—II. Müller cells. Vis Res. 1996;36(16):2381–94.CrossRefPubMed
24.
go back to reference Coughlin BA, Feenstra DJ, Mohr S. Müller cells and diabetic retinopathy. Vis Res. 2017;139:93–100.CrossRefPubMed Coughlin BA, Feenstra DJ, Mohr S. Müller cells and diabetic retinopathy. Vis Res. 2017;139:93–100.CrossRefPubMed
26.
go back to reference Martinet V, et al. Macular edema in central retinal vein occlusion: correlation between optical coherence tomography, angiography and visual acuity. Int Ophthalmol. 2012;32(4):369–77.CrossRefPubMed Martinet V, et al. Macular edema in central retinal vein occlusion: correlation between optical coherence tomography, angiography and visual acuity. Int Ophthalmol. 2012;32(4):369–77.CrossRefPubMed
27.
go back to reference Köferl P, et al. Effects of arteriolar constriction on retinal gene expression and Müller cell responses in a rat model of branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2014;252(2):257–65.CrossRefPubMed Köferl P, et al. Effects of arteriolar constriction on retinal gene expression and Müller cell responses in a rat model of branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2014;252(2):257–65.CrossRefPubMed
28.
go back to reference Rehak M, et al. Retinal gene expression and Müller cell responses after branch retinal vein occlusion in the rat. Investig Ophthalmol Vis Sci. 2009;50(5):2359–67.CrossRef Rehak M, et al. Retinal gene expression and Müller cell responses after branch retinal vein occlusion in the rat. Investig Ophthalmol Vis Sci. 2009;50(5):2359–67.CrossRef
29.
go back to reference Bek T. Capillary closure secondary to retinal vein occlusion. A morphological, histopathological, and immunohistochemical study. Acta Ophthalmol Scand. 1998;76(6):643–8.CrossRefPubMed Bek T. Capillary closure secondary to retinal vein occlusion. A morphological, histopathological, and immunohistochemical study. Acta Ophthalmol Scand. 1998;76(6):643–8.CrossRefPubMed
30.
go back to reference Xin X, et al. Hypoxic retinal Muller cells promote vascular permeability by HIF-1-dependent up-regulation of angiopoietin-like 4. Proc Natl Acad Sci USA. 2013;110(36):E3425–34.CrossRefPubMedPubMedCentral Xin X, et al. Hypoxic retinal Muller cells promote vascular permeability by HIF-1-dependent up-regulation of angiopoietin-like 4. Proc Natl Acad Sci USA. 2013;110(36):E3425–34.CrossRefPubMedPubMedCentral
31.
go back to reference Arrigo A, Aragona E, BattagliaParodi M, Bandello F. Quantitative approaches in multimodal fundus imaging: state of the art and future perspectives. Prog Retin Eye Res. 2023;92: 101111.CrossRefPubMed Arrigo A, Aragona E, BattagliaParodi M, Bandello F. Quantitative approaches in multimodal fundus imaging: state of the art and future perspectives. Prog Retin Eye Res. 2023;92: 101111.CrossRefPubMed
Metadata
Title
Foveal Eversion is Associated with High Persistence of Macular Edema and Visual Acuity Deterioration in Retinal Vein Occlusion
Authors
Alessandro Arrigo
Emanuela Aragona
Alessio Antropoli
Lorenzo Bianco
Andrea Rosolia
Andrea Saladino
Francesco Bandello
Maurizio Battaglia Parodi
Publication date
09-06-2023
Publisher
Springer Healthcare
Keyword
Edema
Published in
Ophthalmology and Therapy / Issue 4/2023
Print ISSN: 2193-8245
Electronic ISSN: 2193-6528
DOI
https://doi.org/10.1007/s40123-023-00734-9

Other articles of this Issue 4/2023

Ophthalmology and Therapy 4/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine